What is Opthea?
Opthea operates at the intersection of biotechnology and ophthalmology, focusing on the development of novel therapies for sight-threatening retinal conditions. The company's core mission revolves around pioneering research into wet age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the most prevalent causes of vision loss globally. Beyond its primary focus on retinal health, Opthea is also exploring therapeutic applications for lymphangioleiomyomatosis (LAM), a rare disorder that presents significant clinical challenges. By leveraging advanced scientific methodologies, the company aims to deliver transformative outcomes for patients while providing value to the broader healthcare ecosystem.
How much funding has Opthea raised?
Opthea has raised a total of $383M across 3 funding rounds:
Stock Offering
$128M
Debt
$170M
Other Financing Round
$85M
Stock Issuance/Offering (2020): $128M with participation from Undisclosed
Debt (2022): $170M led by Carlyle Group and Abingworth
Other Financing Round (2023): $85M supported by Carlyle Group
Key Investors in Opthea
Carlyle Group
The Carlyle Group is a global investment firm specializing in private equity with operations across North America, Europe, Asia, Australia, the Middle East, Africa, and Latin America. The company manages numerous funds focused on four primary investment disciplines: buyouts, venture and growth capital, real estate, and leveraged finance.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies.
Undisclosed Investors
What's next for Opthea?
Looking ahead, the strategic deployment of the $85M will be instrumental in advancing Opthea's clinical development programs. The company is expected to prioritize the progression of its lead candidates through late-stage trials, aiming to secure regulatory approval and eventual commercialization. As the firm transitions from a research-heavy entity to a more mature clinical-stage organization, the focus will likely shift toward optimizing manufacturing processes and strengthening its intellectual property portfolio. Investors and stakeholders will be closely monitoring the upcoming data readouts, which will serve as key indicators of the company's long-term viability and its potential to disrupt the current standard of care in retinal disease management.
See full Opthea company page
